DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 214 filers reported holding DENALI THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,388,612 | -31.8% | 406,622 | -2.4% | 0.01% | -30.0% |
| Q2 2023 | $12,299,266 | +26.0% | 416,783 | -1.6% | 0.02% | +25.0% |
| Q1 2023 | $9,761,242 | -19.4% | 423,665 | -2.8% | 0.02% | -23.8% |
| Q4 2022 | $12,116,066 | -10.9% | 435,673 | -1.7% | 0.02% | -12.5% |
| Q3 2022 | $13,599,000 | +2.5% | 443,101 | -1.7% | 0.02% | +9.1% |
| Q2 2022 | $13,264,000 | -21.3% | 450,689 | -14.0% | 0.02% | 0.0% |
| Q1 2022 | $16,861,000 | -27.5% | 524,131 | +0.5% | 0.02% | -21.4% |
| Q4 2021 | $23,255,000 | -16.3% | 521,408 | -5.4% | 0.03% | -17.6% |
| Q3 2021 | $27,797,000 | -37.5% | 550,987 | -2.8% | 0.03% | -35.8% |
| Q2 2021 | $44,463,000 | +37.6% | 566,845 | +0.2% | 0.05% | +29.3% |
| Q1 2021 | $32,311,000 | -8.9% | 565,866 | +33.7% | 0.04% | -4.7% |
| Q4 2020 | $35,460,000 | – | 423,353 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |